Proteins and Peptides

08 Oct 2019 Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis
08 Oct 2019 Intarcia Therapeutics Provides Regulatory Update - FDA Accepts Resubmitted New Drug Application For ITCA 650
08 Oct 2019 Stealth BioTherapeutics Presents Data on SBT-272 in Neurodegeneration
08 Oct 2019 Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis
08 Oct 2019 Axcella Provides Progress Updates for Liver Program Candidates AXA1125 and AXA1957
03 Oct 2019 Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor-Localized Immunotherapy
02 Oct 2019 Ra Pharmaceuticals Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for gMG
02 Oct 2019 Evolus Receives Approval for Nuceiva™ in the European Union
01 Oct 2019 TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic Cancer
01 Oct 2019 Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 for HPV16-driven Head and Neck Squamous Cell Carcinoma
29 Sep 2019 Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Malignant Ascites
29 Sep 2019 Bicycle Therapeutics Announces Presentation of Updated Data from Phase I/IIa Trial Evaluating BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress
27 Sep 2019 89bio Announces Dosing of First Patients in NASH Study and Issuance of Composition of Matter Patent
27 Sep 2019 Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Triple-Negative Breast Cancer Patients at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
27 Sep 2019 Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy
27 Sep 2019 Noveome Biotherapeutics, Inc. Initiates Phase 1 Open Label Clinical Trial Evaluating Intranasal Delivery of Lead Candidate ST266 Targeting the Optic Nerve and Brain
25 Sep 2019 Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease
24 Sep 2019 Entera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism
24 Sep 2019 Zealand Pharma achieves primary and all key secondary endpoints in pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia
23 Sep 2019 Mochida obtains marketing approval for teriparatide biosimilar in Japan
23 Sep 2019 Announcement of Receiving Manufacturing and Marketing Approval for Darbepoetin Alpha Biosimilars in Japan
22 Sep 2019 Once-weekly somapacitan demonstrates similar one-year height gains compared to daily somatropin in a phase 2 trial in children with growth hormone deficiency
20 Sep 2019 FDA approves Rybelsus® (semaglutide), the first GLP-1 analog treatment available in a pill for adults with type 2 diabetes
19 Sep 2019 Dance Biopharm Presents Phase 2 Clinical Data Highlighting Rapid Effects of Inhaled Human Insulin at European Association for the Study of Diabetes Meeting
18 Sep 2019 Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up